Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Now a huge disconnect between the US price, it opened flat which means t he 200% jump remains
It’s only 2.30 Alan! Give it time, US up 200%!!!!
It was 3 times higher than this just a couple of months ago and they seem to have done so well since that drop, you would think this would have gone a lot higher today. It looks like an absolute solid company which is rare on LSE
Had my fingers and toes burnt too many times… as tempting as it may be, I’m not buying anymore…. even if I knew it was another 50% tomorrow. However, I may think about it once I recoup some losses !
Burn them all!! About to pop now with 1.67 to sell
Enjoy :)
Up to No.5 in today's top share risers and still climbing , 50% and it will be No1
Well done to those who didn't sell, still time to buy.
Think the key difference between the Feb update and the one today is:
Total U.S. Accrufer® prescriptions increased to c. 77,000 in 2023 and totalled c. 28,800 in Q1 2024
So basically they sold in Q1 24 just under what they sold in half year of 2023. Effectively doubling their sales.
Should hop now we are climbing the leaderboard! This is hugely undervalued atm
1.67 to buy atm
200% up in the US 18 here… someone in the us was happy to pay a monumental premium so expect a lift past 2 if t he y open strong again
@smyths Yes it went blue before yesterday's close, engines started, and today we have lift-off!
I hope you are happy now :) lol
1.59 to buy atm
Wow.. $SHIEF (ticker symbol in Nasdaq),
Is up 200%!
Amazing
Yeah, the smart traders will be in and out long before the risk of getting caught out but the rest will be burnt and you can be damn sure Greg won’t even have an ounce of contrition for his actions.
I also suspect that’ll be the time the directors buy in which they will think ‘softens the blow’
HarChris
You are spot on with your observation. Plenty of new investors to lure in to facilitate their next placing. In the mean time few champion traders will trade to earn some quick bucks I suppose.
GLA
Consensus seems to be positive after meeting report. More buys than sells. Next quarter figures will need to be positive to maintain momentum.
11.11% up... looking forward to rerating.
1.45/1.55
atm
Ripe for a takeover
Feels like a great opportunity to be buying at these levels
Just for balance this is what the CEO said in late Sept 2023 as he also announced Q3 2023 prescription numbers would exceed 28,000.
"We believe our standout H1 2023 results, KPI achievements and expectations for continued Q3 2023 growth put us on track to reach total 2023 Accrufer® prescriptions of 100,000 to 130,000. This is a major corporate milestone for Shield and forms the foundation for future growth. Looking ahead, we have defined additional initiatives to improve our gross-to-net, continue the growth in Accrufer® prescriptions and market adoption and expand market access. Our commercial results provide validation of our strategic plan and give us access to important growth capital. The new $20 million term loan announced today and an equity financing of up to $7.4 million will put us on a steady path to reach our guidance of cash flow breakeven, expected by year-end 2024."
So the breakeven has extended by over 6 months, the actual Q3 prescription numbers were miles off and the Q4 2023 and Q1 2024 are actually at the level we were told we were at 6 months ago. The fundraise was done at 8p and SP was over 10p the day before.
1.44 to buy atm
Profit in 2025 fully funded until then
sounds too good to be true.